Pregledni rad

THE ROLE OF ANTI-TNF THERAPY IN ULCERATIVE COLITIS

SILVIJA ČUKOVIĆ-ČAVKA ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zavod za gastroenterologiju i hepatologiju, Klinika za unutrašnje bolesti, Zagreb, Hrvatska
BORIS VUCELIĆ ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zavod za gastroenterologiju i hepatologiju, Klinika za unutrašnje bolesti, Zagreb, Hrvatska
MARIJA CRNČEVIĆ UREK ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zavod za gastroenterologiju i hepatologiju, Klinika za unutrašnje bolesti, Zagreb, Hrvatska
MARKO BRINAR ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zavod za gastroenterologiju i hepatologiju, Klinika za unutrašnje bolesti, Zagreb, Hrvatska
NIKŠA TURK ; Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zavod za gastroenterologiju i hepatologiju, Klinika za unutrašnje bolesti, Zagreb, Hrvatska

Sažetak

Anti-TNF-alfa molecules are currently being used to treat ulcerative colitis regarding to the fact that TNF-alpha has an important role in the pathogenesis of IBD . Although these drugs improved the therapy of patients, immunogenicity limits their potential for clinical use. Infliximab and adalimumab are effective for induction and maintenance of remission in outpatients with moderate to severe steroid-refractory ulcerative colitis. Biologics can be a drug of choice for patients with refractory proctitis and refractory pouchitis. In hospitalized patients with steroid-resistant severe ulcerative colitis who are candidates for colectomy, infliximab may be second-line option. Adequate long-term maintenance therapy with anti-TNF is required after rescue therapy for a sustained benefit. Regarding to the known risk for side-effects of anti-TNF drugs especially in patients concomitantly treated with thiopurines it is urgent future research.

Ključne riječi

ulcerative colitis; therapy; anti-TNF drug; infliximab; adalimumab

Hrčak ID:

111691

URI

https://hrcak.srce.hr/111691

Datum izdavanja:

28.11.2013.

Podaci na drugim jezicima: hrvatski

Posjeta: 2.496 *